Published • loading... • Updated
Cognizant and Benchling Selected as Partners to Accelerate Kyowa Kirin's R&D
Cognizant will help deploy Benchling’s platform, which links lab instruments to structured data and AI models for faster drug discovery.
- On August 16, 2026, Kyowa Kirin announced it selected Benchling as its AI research platform, with Cognizant providing implementation support at Tokyo Research Park and Fuji Research Park sites.
- Kyowa Kirin, which has contributed to biotechnology for more than 70 years, seeks to address unmet medical needs by integrating "disease science" with "drug discovery technologies" to accelerate innovation.
- Benchling embeds AI into daily workflows connected to years of experimental data, while Cognizant manages platform deployment, system maintenance, and data migration across the research lifecycle.
- Nobuhiko Watanabe, President and Representative Director of Cognizant Japan, said the initiative is expected to "significantly improve drug discovery efficiency" and strengthen the company's position in the Japanese market.
- Trusted by more than 1,300 companies worldwide, Benchling enables scientists to capture, connect, and act on data across the entire R&D lifecycle, aiming to deliver medicines to patients sooner.
Insights by Ground AI
41 Articles
41 Articles
How Cognizant’s AI-Powered Benchling Deployment at Kyowa Kirin (CTSH) Has Changed Its Investment Story
Cognizant announced it will support the introduction and implementation of Benchling’s AI-driven R&D platform at Kyowa Kirin’s research sites in Japan, providing end-to-end services from setup and data migration to system integration and maintenance. This collaboration deepens Cognizant’s presence in life sciences while highlighting how AI-enabled data management and automated workflows can reshape pharmaceutical research productivity and operat…
Coverage Details
Total News Sources41
Leaning Left4Leaning Right3Center27Last UpdatedBias Distribution79% Center
Bias Distribution
- 79% of the sources are Center
79% Center
12%
C 79%
Factuality
To view factuality data please Upgrade to Premium
